

Advancing therapies for patients resistant to current treatments

Company Overview:

- A clinical-stage company advancing **multi-modality oncology therapies**
- **Leadership team with proven track record** in oncology drug development and commercialization (e.g., ONIVYDE®), including successful IPO (e.g., PharmaEngine)
- International footprint across **Europe (France, Switzerland) and Taiwan** (global headquarters)
- Raised **CHF 75.5M (> USD 90M) to date**; Series B financing ongoing, preparing for IPO in 2027

Our Team:



Dr C. Grace Yeh
Chairperson & CEO
Biotech entrepreneur and company builder




Dr Alain Herrera
Chief Medical Officer
Oncology clinical development expert



Dr Armand de Gramont
President of R&D
Oncology R&D expert

CORPORATE STRUCTURE AND PARTNERSHIPS




To support its planned IPO in Taiwan, Onward has restructured with a new Taiwan headquarters in Q4 2025.

Multiple assets:

1. Biomunex (OT-A201): through a global license agreement and equity investment
2. Emercell (OT-C001): acquired via equity investment
3. ICM (OT-S00X): through worldwide license
4. OT-A30X: internal discovery


A DIFFERENTIATED PIPELINE ADDRESSING CANCER RESISTANCE

Our multi-modality pipeline:




OT-A201 is a first-in-class bispecific antibody targeting novel resistance mechanisms

- Solid tumor: Phase 1b initiated (2026H1)
- Hematology: Phase 1b planned (2026H2)




OT-C001 is an off-the-shelf NK cell therapy in combination with antibodies

- Phase 1 ongoing (to be completed in 2026Q4)



OT-S00X is a novel small molecule to overcome tumor resistance by targeting cancer metabolism

- Lead optimization (candidate to be selected in 2026)



OT-A30X is a first-in-class multi-specific program with the flexibility to expand into bispecific, tri-specific, and ADC modalities

- Discovery stage

Traction / Milestones:



Phase 1a

- Favorable safety profile
- Early signals in unselected heavily-treated patients
- Combination potential

(OT-A201 and OT-C001)



High Unmet Needs

Broad patient population with **> 30% relapse and refractory** rates in advanced cancers



Strong partnering potential

- OT-A201: **US\$1B+** potential (comparable transactions)
- OT-C001: **Versatile platform** for combination with antibodies

CONTACT INFORMATION



Website:

www.onward-therapeutics.com



Contact us:

info@onward-therapeutics.com



Onward Therapeutics, Inc. (昂沃生物科技)

2F, No. 60, Songjiang Road, Taipei, Taiwan 104

Onward Therapeutics SA

Biopôle, Route de la Corniche 8, 1066 Epalinges, Switzerland

Onward Therapeutics France SAS

28 bis Rue de Richelieu, 75001 Paris, France

QR Code:

